RCUS logo

RCUS Arcus Biosciences, Inc.

New York Stock Exchange · Biotechnology · Healthcare

$15.78
+0.02 (+0.13%)

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an…

Market Cap: $2.27Barcusbio.com

Price

$28.62+11.45%
$22.12$25.11$28.09$31.08
May 1Aug 7

Social Signal Score

40
5d
—
30d
30
1 mentions
+0.0%
60d
42
7 mentions
+0.0%
90d
48
10 mentions
+0.0%
news: 10

Analyst Ratings

18 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 3Sell 0Strong Sell 0
Avg price target$40.67+157.7%
Low $23Median $42.5High $50
Current Consensus

Revenue

$9.00M
$0.00$118.17M$236.33M$354.50M
Mar 2017Sep 2026

Analyst Estimates

FY2025
$-3.55
$-3.73–$-3.07
4 analysts
FY2026
$-3.63
$-3.91–$-3.15
10 analysts
FY2027
$-3.27
$-4.27–$-2.27
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Terry J. Rosen
Sector
Healthcare
Industry
Biotechnology
Employees
601
Beta
0.81
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-1.06
arcusbio.com